Metablok is our lead drug candidate for treating inflammation in the lungs.
Arch Biopartners is now focused on beginning a Phase II Trial to investigate Metablok’s efficacy in treating inflammation-related lung injury in COVID-19 infected patients. In the worst cases of COVID-19 infection, fatalities are often linked to severe lung inflammation due to viral pneumonia, and subsequent respiratory failure.